Clinical trial · Interventional
Exergaming Intervention and Breast Cancer Biomarkers in Black Women
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Overview: This is a 6 month, two-arm randomized clinical trial using comparing exergaming to a control group. The investigators will randomize Black sedentary overweight/obese women to Wii Fit exercise (n=50) or the control arm (n=50). Women in the Wii Fit exercise group will come to the Georgetown community-based exercise facility 3 days/wk. The control group will be asked to maintain their current daily activities and not to exercise for the duration of the study. Based on the investigators previous findings that women who engage in 75-150 mins/wk of brisk walking had an 18% decreased risk of breast cancer, the investigators will target this level of activity in the investigators intervention arm. Also, this 150 min/week of physical activity meets the current recommendations of the American College of Sports Medicine (ACSM) and the US Department of Health and Human Services for healthy individuals and is in line with recommendation of the American Cancer Society (ACS) for cancer prevention.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Obesity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exergaming | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Exergaming
- description
- Exercise Intervention: Participants in the Wii Fit exergaming group will have a goal of 150 min/wk of moderate intensity exercise for the last 5 mo of the 6 mo intervention. Heart rate (HR) monitors will quantify exercise intensity. Participants will exercise at a HR equal to 45-65% of their VO2max. Participants will be instructed by the exercise physiologist on how to achieve the required HR. The training will consist of 3 days/wk of supervised Wii Fit physical activity. Exercise duration will increase gradually from 75 to 150 min/wk by wk 477. Thereafter, women will maintain \>150 min/wk of moderate-intensity physical activity. Participants will complete daily exercise diaries recording the type and duration of physical activity, and HR.
- interventionNames
- Other: Exergaming
- type
- NO_INTERVENTION
- label
- Control
- description
- Control Group: After baseline testing the control group will be asked to maintain their current daily activities for the duration of the study. The control group will have the option to exercise at the Wii Fit stations following their completion of the study. They will receive the same measures as the exercise group.
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 40 Years
- Maximum age
- 59 Years
Show eligibility criteria text
Inclusion Criteria: * Black women * BMI ≥28 kg/m2 but ≤ 350 pounds of body weight * Aged 40-59 years * Sedentary (\<60 min/wk exercise for past 6 months * Never been diagnosed with cancer * Ability to read and speak English and to provide meaningful consent * No physical limitations preventing them from exercising * Medical clearance by a health practitioner. Exclusion Criteria: * History of cancer * Uncontrolled hypertension and medically treated diabetes * Current enrollment in another physical activity and/or dietary study or a diet/weight loss program * Pregnancy * Inability to consent to study participation and complete assessments * Telephone inaccessibility * Physical limitations to exercise inability to commit to the intervention schedule
References
Publications (1)
- DERIVEDHicks J, Dash C, Smith D, Hagberg J, Makambi K, Adams-Campbell L. Is exergaming a viable exercise option for obese black women? Contemp Clin Trials. 2025 Apr;151:107846. doi: 10.1016/j.cct.2025.107846. Epub 2025 Feb 12. PMID 39952553